Clinical Trials Logo

Citation(s)

Phase II Study of the PARP Inhibitor, Olaparib, in Adult Patients With Recurrent/Metastatic Ewing's Sarcoma Following Failure of Prior Chemotherapy

Details for clinical trial NCT01583543